Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Vladimír, Kryštof"'
Autor:
Thalia Delgado, Denisa Veselá, Hana Dostálová, Vladimír Kryštof, Veronika Vojáčková, Radek Jorda, Alejandro Castro, Jeanluc Bertrand, Gildardo Rivera, Mario Faúndez, Miroslav Strnad, Christian Espinosa-Bustos, Cristian O. Salas
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 649 (2024)
Bcr-Abl is an oncoprotein with aberrant tyrosine kinase activity involved in the progression of chronic myeloid leukemia (CML) and has been targeted by inhibitors such as imatinib and nilotinib. However, despite their efficacy in the treatment of CML
Externí odkaz:
https://doaj.org/article/6759ae3341e1454eb52b04d4fd0fb76d
Autor:
Markéta Kovalová, Libor Havlíček, Stefan Djukic, Jana Škerlová, Miroslav Peřina, Tomáš Pospíšil, Eva Řezníčková, Pavlína Řezáčová, Radek Jorda, Vladimír Kryštof
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 161, Iss , Pp 114492- (2023)
Targeting cyclin-dependent kinase 7 (CDK7) provides an interesting therapeutic option in cancer therapy because this kinase participates in regulating the cell cycle and transcription. Here, we describe a new trisubstituted pyrazolo[4,3-d]pyrimidine
Externí odkaz:
https://doaj.org/article/ebadbe56eb674ba785bd3c09da68b0d5
Autor:
Monika Tomanová, Karolína Kozlanská, Radek Jorda, Lukáš Jedinák, Tereza Havlíková, Eva Řezníčková, Miroslav Peřina, Pavel Klener, Alexandra Dolníková, Petr Cankař, Vladimír Kryštof
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 24, p 16169 (2022)
Therapy of FLT3-positive acute myeloid leukemia still remains complicated, despite the availability of newly approved kinase inhibitors. Various strategies to avoid the reduced efficacy of therapy have been explored, including the development of dual
Externí odkaz:
https://doaj.org/article/116746868f804df5a2709a06c35a7b83
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 23, p 15143 (2022)
Purine nucleosides represent an interesting group of nitrogen heterocycles, showing a wide range of biological effects. In this study, we designed and synthesized a series of 6,9-disubstituted and 2,6,9-trisubstituted purine ribonucleosides via conse
Externí odkaz:
https://doaj.org/article/150344cbae4044799a6743d39efc459e
Autor:
Jeanluc Bertrand, Hana Dostálová, Vladimír Kryštof, Radek Jorda, Thalía Delgado, Alejandro Castro-Alvarez, Jaime Mella, David Cabezas, Mario Faúndez, Christian Espinosa-Bustos, Cristian O. Salas
Publikováno v:
Pharmaceutics, Vol 14, Iss 6, p 1294 (2022)
We report 31 new compounds designed, synthesized and evaluated on Bcr-Abl, BTK and FLT3-ITD as part of our program to develop 2,6,9-trisubstituted purine derivatives as inhibitors of oncogenic kinases. The design was inspired by the chemical structur
Externí odkaz:
https://doaj.org/article/e164559cd3e445158c0980316b7a2f9f
Autor:
Markéta Kovalová, Joseph Peter Baraka, Václav Mik, Radek Jorda, Lei Luo, Hao Shao, Vladimír Kryštof
Publikováno v:
Expert Opinion on Therapeutic Patents. 33:67-87
Autor:
Beatričė Razmienė, Eva Řezníčková, Vaida Dambrauskienė, Radek Ostruszka, Martin Kubala, Asta Žukauskaitė, Vladimír Kryštof, Algirdas Šačkus, Eglė Arbačiauskienė
Publikováno v:
Molecules, Vol 26, Iss 21, p 6747 (2021)
A library of 2,4,6,7-tetrasubstituted-2H-pyrazolo[4,3-c]pyridines was prepared from easily accessible 1-phenyl-3-(2-phenylethynyl)-1H-pyrazole-4-carbaldehyde via an iodine-mediated electrophilic cyclization of intermediate 4-(azidomethyl)-1-phenyl-3-
Externí odkaz:
https://doaj.org/article/c1e5ffbbb6c3420e803de16af82fd513
Adamantane-Substituted Purines and Their β-Cyclodextrin Complexes: Synthesis and Biological Activity
Autor:
Michal Rouchal, Jana Rudolfová, Vladimír Kryštof, Veronika Vojáčková, Richard Čmelík, Robert Vícha
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 23, p 12675 (2021)
Cyclin-dependent kinases (CDKs) play an important role in the cell-division cycle. Synthetic inhibitors of CDKs are based on 2,6,9-trisubstituted purines and are developed as potential anticancer drugs; however, they have low solubility in water. In
Externí odkaz:
https://doaj.org/article/c111a4005877411e891420cb63a64840
Autor:
Radek Jorda, Libor Havlíček, Miroslav Peřina, Veronika Vojáčková, Tomáš Pospíšil, Stefan Djukic, Jana Škerlová, Jiří Grúz, Nicol Renešová, Pavel Klener, Pavlína Řezáčová, Miroslav Strnad, Vladimír Kryštof
Publikováno v:
Journal of Medicinal Chemistry. 65:8881-8896
Publikováno v:
Medicinal Chemistry. 18:484-496
Background: Cycle-regulating and transcriptional cyclin-dependent kinases (CDKs) are attractive targets in cancer drug development. Several CDK inhibitors have already been obtained or are close to regulatory approval for clinical applications. Objec